Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program

Dec 12, 2024
1 min read

CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and manufacturing protein-based medicines. He then walks us through the company’s development plans.

https://vimeo.com/1038699160

Recent Posts

See All

Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - the company believes it has its own best in class insulin leveraging this

Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight